MANGOCEUTICALS INC
MGRXNASDAQTrading Snapshot
- Day Range
- $0.25 – $0.26
- 52-Week Range
- $0.16 – $2.41
- Volume (shares)
- 380,753
- Avg Volume (shares)
- —
- Shares Outstanding
- 22.2M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- $456,021
- Last Q Revenue
- $68,757
- P/E Ratio
- —
- P/S Ratio
- 17.5x
- EPS (TTM)
- $-1.14
- Dividend Yield
- —
- Dilution (1yr)
- +389.5%
MANGOCEUTICALS INC
MGRX
StockOtter · stockotter.spaceAbout MANGOCEUTICALS INC
Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men. These offerings are primarily delivered through a telemedicine platform. The company's product line includes treatments for erectile dysfunction, marketed under the 'Mango' brand. Consumers can purchase these items directly from its official online portal, mangorx.com. Established in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as an affiliate of Cohen Enterprises, Inc.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Analyzing Mangoceuticals (NASDAQ:MGRX) & Quest Diagnostics (NYSE:DGX)
Quest Diagnostics (NYSE: DGX - Get Free Report) and Mangoceuticals (NASDAQ: MGRX - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the stre
Mangoceuticals (NASDAQ: MGRX) closes 74% premium stock sale with warrants
What happened Mangoceuticals, Inc. (NASDAQ: MGRX) closed a registered direct offering on October 9, 2026 for about $492,750. The company sold 657,000 shares of common stock together with 657,000 warrants at $0.75 per uni
Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close
Transaction follows a $2. 5 million strategic investment commitment at MangoRx IP Holdings to support intellectual property commercialization DALLAS, TX, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MG
Nike Posts Mixed Q1 Results, Joins Mangoceuticals And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday.
Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche
Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company's Antiviral Intellectual Property Portfolio with No Issuance of MGRX Common Stock
Head to Head Survey: Mangoceuticals (NASDAQ:MGRX) and Chemed (NYSE:CHE)
Chemed (NYSE: CHE - Get Free Report) and Mangoceuticals (NASDAQ: MGRX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of th